nach oben

Strahlentherapie und Onkologie

Erschienen in:

01.04.2014 | Original article

Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy

verfasst von: T. Langsenlehner, M.D., E.-M. Thurner, W. Renner, A. Gerger, K.S. Kapp, U. Langsenlehner

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Vascular endothelial growth factor-A (VEGF-A), a key regulator of tumor-induced angiogenesis, is critical for tumor growth and metastasization. The goal of the present study was to evaluate the prognostic value of VEGF single nucleotide polymorphisms (SNPs) and haplotypes for clinical recurrence after definitive radiotherapy for prostate cancer.

Patients and methods

The association of seven VEGF-A polymorphisms and their haplotypes with clinical recurrence (defined as the occurrence of local recurrence and/or distant metastases) in 496 prostate cancer patients treated with definitive radiotherapy were investigated. Genotypes were determined by 5’-nuclease (TaqMan) assays; haplotypes were analyzed using the Haploview program.

Results

Within a median follow-up time of 80 months, 44 patients (9 %) developed clinical recurrences. Haplotype analysis showed two separate blocks of high-linkage disequilibrium, formed by five polymorphisms (− 2578C > A, − 2489C > T, − 1498C > T, − 634G > C, − 7C > T) upstream of the coding sequence (CCCCC, ATTGC, CCCGC, ATTGT) and two polymorphisms (936C > T, 1612G > A) downstream of the coding sequence (CA, CG, TG). Carriers of at least 1 copy of the ATTGC haplotype were at higher risk of recurrence (hazard ratio [HR] 3.83; 95 %CI 1.48–9.90, p = 0.006); for carriers of 2 copies, the HR was 4.85 (95 %CI 1.72–13.6; p = 0.003). In multivariate analysis, patients harboring at least one copy of the ATTGC haplotype remained at increased risk of recurrence (HR 3.63, 95 %CI 1.38–9.55, p = 0.009); in patients carrying 2 copies, the HR was 4.72 (95 %CI 1.64–13.6, p = 0.004).

Conclusion

Our findings indicate that the VEGF-A ATTGC haplotype may predict clinical recurrence in prostate cancer patients treated with radiotherapy.

Bayer C, Vaupel P (2012) Acute versus chronic hypoxia in tumors: controversial data concerning time frames and biological consequences. Strahlenther Onkol 188:616–627PubMedCrossRef

Berns EM, Klijn JG, Look MP et al (2003) Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer. Clin Cancer Res 9:1253–1258PubMed

Brogan IJ, Khan N, Isaac K et al (1999) Novel polymorphisms in the promoter and 5’ UTR regions of the human vascular endothelial growth factor gene. Hum Immunol 60:1245–1249PubMedCrossRef

Burstein HJ, Chen YH, Parker LM et al (2008) VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 14:7871–7877PubMedCrossRef

Dayyani F, Gallick GE, Logothetis CJ et al (2011) Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103:1665–1675PubMedCrossRef

Duque JL, Loughlin KR, Adam RM et al (1999) Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 54:523–527PubMedCrossRef

Eng L, Azad AK, Habbous S et al (2012) Vascular endothelial growth factor pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a systematic review and meta-analysis. Clin Cancer Res 18:4526–4537PubMedCrossRef

Erpolat OP, Gocun PU, Akmansu M et al (2013) Hypoxia-related molecules HIF-1α, CA9, and osteopontin: predictors of survival in patients with high-grade glioma. Strahlenther Onkol 189:147–154PubMedCrossRef

Escudier B, Szczylik C, Porta C et al (2012) Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol 9:327–337PubMedCrossRef

10.

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676PubMedCrossRef

11.

Fontanini G, Boldrini L, Chine S et al (1999) Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79:363–369PubMedCentralPubMedCrossRef

12.

García-Closas M, Malats N, Real FX et al (2007) Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 3:e29PubMedCentralPubMedCrossRef

13.

George DJ, Halabi S, Shepard T et al (2001) Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 7:1932–1936PubMed

14.

Green MM, Hiley CT, Shanks JH et al (2007) Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 67:84–90PubMedCrossRef

15.

Grothey A, Ellis LM (2008) Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies. Cancer J 14:170–177PubMedCrossRef

16.

Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027PubMedCrossRef

17.

Jang MJ, Jeon YJ, Kim JW et al (2013) Association of VEGF and KDR single nucleotide polymorphisms with colorectal cancer susceptibility in Koreans. Mol Carcinog 52:E60–69PubMedCrossRef

18.

Kelly WK, Halabi S, Carducci M et al (2012) Randomized, double-blind, placebo controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 30:1534–1540PubMedCentralPubMedCrossRef

19.

Kim DH, Xu W, Kamel-Reid S et al (2010) Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 21:1179–1188PubMedCrossRef

20.

Kobayashi T, Liu X, Wen FQ et al (2006) Smad3 mediates TGFbeta 1 induction of VEGF production in lung fibroblasts. Biochem Biophys Res Commun 339:290–295PubMedCrossRef

21.

Koukourakis MI, Papazoglou D, Giatromanolaki A et al (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293–298PubMedCrossRef

22.

Langenbacher M, Abdel-Jalil RJ, Voelter W et al (2013) In vitro hypoxic cytotoxicity and hypoxic radiosensitization. Efficacy of the novel 2-nitroimidazole N,N,N-tris[2-(2-nitro-1H-imidazol-1-yl)ethyl]amine. Strahlenther Onkol 189:246–254PubMedCrossRef

23.

Lee JC, Chow NH, Wang ST et al (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36:748–753PubMedCrossRef

24.

Li A, Gao P, Wang Z et al (2013) Positive association of the vascular endothelial growth factor-A + 405 GG genotype and poor survival in stage I–II gastric cancer in the Northern Chinese population. Mol Biol Rep 40:2741–2748PubMedCrossRef

25.

McShane L, Altman DG, Sauerbrei W et al (2005) for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Eur J Cancer 41:1690–1696PubMedCrossRef

26.

Minchenko A, Salceda S, Bauer T et al (1994) Hypoxia regulatory elements of the human vascular endothelial growth factor gene. Cell Mol Biol Res 40:35–39PubMed

27.

Oh SY, Kwon HC, Kim SH et al (2013) The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13:43PubMedCentralPubMedCrossRef

28.

Renner W, Kotschan S, Hoffmann C et al (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448PubMedCrossRef

29.

Schultz A, Lavie L, Hochberg I et al (1999) Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. Circulation 100:547–552PubMedCrossRef

30.

Seibold ND, Schild SE, Gebhard MP et al (2013) Prognostic impact of VEGF and FLT-1 receptor expression in patients with locally advanced squamous cell carcinoma of the head and neck. Strahlenther Onkol 189:639–646PubMedCrossRef

31.

Shariat SF, Anwuri VA, Lamb DJ et al (2004) Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 22:1655–1663PubMedCrossRef

32.

Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68:978–989PubMedCentralPubMedCrossRef

33.

Stevens A, Soden J, Brenchley PE et al (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 63:812–816PubMed

34.

Timke C, Zieher H, Roth A et al (2008) Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy. Clin Cancer Res 14:2210–2219PubMedCrossRef

35.

Vergis R, Corbishley CM, Norman AR et al (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9:342e351CrossRef

36.

Watson CJ, Webb NJ, Bottomley MJ et al (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235PubMedCrossRef

37.

Yamamori M, Sakaeda T, Nakamura T et al (2004) Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 325:144–150PubMedCrossRef

38.

Yuan A, Yu CJ, Chen WJ et al (2000) Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer. Int J Cancer 89:475–483PubMedCrossRef

Titel: Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy
verfasst von: T. Langsenlehner, M.D.
E.-M. Thurner
W. Renner
A. Gerger
K.S. Kapp
U. Langsenlehner
Publikationsdatum: 01.04.2014
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 4/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0503-2

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

DEGRO practical guidelines: radiotherapy of breast cancer III—radiotherapy of the lymphatic pathways

Kosmetische Ergebnisse nach adjuvanter Bestrahlung bei brusterhaltender Operation wegen Mammakarzinom

Bevacizumab treatment in malignant meningioma with additional radiation necrosis

Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma